Tahir Amin of I-MAK speaks to IP-Watch about Natco’s attempt to obtain a compulsory licence for exporting two cancer drugs to Nepal and the concerns surrounding the Indian patent office’s procedure.
Partner with us now to build a more just and equitable medicine system for all. Notice: JavaScript is required for this content.